Novo Nordisk's Semaglutide Trials Miss Primary Endpoints but Offer Biomarker Insights

Novo Nordisk presented new topline results from their Evoke and Evoke+ phase 3 trials of semaglutide, an oral GLP-1 drug, at the CTAD conference. The trials did not meet their primary endpoints, but highlighted biomarker findings that offer insight into Alzheimer's pathobiology. The results demonstrated reductions of up to 10% in biomarkers linked to neuroinflammation and Alzheimer's disease. Full results will be presented at the International Conference on Alzheimer's and Parkinson's Diseases in March 2026.